Question of Using Valganciclovir for Cytomegalovirus (CMV) Infection Prophylaxis in Post–Liver Transplant Recipients
- 1 June 2006
- journal article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 12 (6) , 1020-1021
- https://doi.org/10.1002/lt.20749
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Does Valganciclovir Hydrochloride (Valcyte) Provide Effective Prophylaxis Against Cytomegalovirus Infection in Liver Transplant Recipients?Transplantation Proceedings, 2005
- Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipientsLiver Transplantation, 2005
- Cost-Effectiveness of Organ Donation: Evaluating Investment into Donor Action and Other Donor InitiativesAmerican Journal of Transplantation, 2004
- Pharmacokinetics of valganciclovir and ganciclovir in renal impairmentClinical Pharmacology & Therapeutics, 2002
- Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant RecipientsAntimicrobial Agents and Chemotherapy, 2000